Celcuity (NASDAQ:CELC) Rating Reiterated by Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Celcuity (NASDAQ:CELC) in a research report released on Friday, Benzinga reports. The firm currently has a $24.00 target price on the stock.

A number of other research analysts also recently commented on the stock. Craig Hallum increased their price objective on shares of Celcuity from $20.00 to $25.00 and gave the company a buy rating in a research note on Thursday, March 28th. Stifel Nicolaus began coverage on shares of Celcuity in a research report on Thursday, February 22nd. They issued a buy rating and a $40.00 price target on the stock. Finally, HC Wainwright restated a buy rating and issued a $27.00 price target on shares of Celcuity in a research report on Thursday, March 28th.

Celcuity Trading Down 1.2 %

NASDAQ CELC opened at $18.09 on Friday. Celcuity has a 12 month low of $8.39 and a 12 month high of $22.19. The company has a debt-to-equity ratio of 0.26, a current ratio of 13.43 and a quick ratio of 13.43. The company has a market capitalization of $550.84 million, a price-to-earnings ratio of -6.72 and a beta of 0.78. The company’s fifty day moving average price is $17.47 and its two-hundred day moving average price is $14.46.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Vanguard Group Inc. increased its holdings in shares of Celcuity by 3.7% in the 4th quarter. Vanguard Group Inc. now owns 820,776 shares of the company’s stock worth $11,959,000 after acquiring an additional 29,181 shares during the period. Perceptive Advisors LLC acquired a new stake in shares of Celcuity in the 4th quarter worth about $21,583,000. Barclays PLC increased its holdings in shares of Celcuity by 652.8% in the 4th quarter. Barclays PLC now owns 24,021 shares of the company’s stock worth $350,000 after acquiring an additional 20,830 shares during the period. Nuveen Asset Management LLC increased its holdings in shares of Celcuity by 36.1% in the 4th quarter. Nuveen Asset Management LLC now owns 32,441 shares of the company’s stock worth $473,000 after acquiring an additional 8,603 shares during the period. Finally, Royal Bank of Canada increased its holdings in shares of Celcuity by 12.0% in the 4th quarter. Royal Bank of Canada now owns 18,909 shares of the company’s stock worth $276,000 after acquiring an additional 2,020 shares during the period. 63.33% of the stock is currently owned by institutional investors.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.